{"id":549626,"date":"2026-04-17T04:59:06","date_gmt":"2026-04-17T02:59:06","guid":{"rendered":"https:\/\/www.dynseo.com\/sclerose-en-plaques-sep-symptomes-et-prise-en-charge-dynseo-2\/"},"modified":"2026-04-17T04:59:59","modified_gmt":"2026-04-17T02:59:59","slug":"multiple-sclerosis-ms-symptoms-and-management","status":"publish","type":"post","link":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/","title":{"rendered":"Multiple Sclerosis (MS): Symptoms and Management"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Article HTML&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;Contenu&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_code admin_label=&#8221;HTML import\u00e9&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<style type=\"text\/css\">\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Montserrat:wght@600;700;800&family=Poppins:wght@400;500;600&display=swap');\n        * { margin: 0; padding: 0; box-sizing: border-box; }\n.dbi-art-d20b5e { font-family: 'Poppins', sans-serif; line-height: 1.8; color: #333; background-color: #f8f9fa; }\n.dbi-art-d20b5e .container { max-width: 900px; margin: 0 auto; padding: 20px; }\n.dbi-art-d20b5e .article-header { background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 60px 20px; text-align: center; border-radius: 0 0 30px 30px; margin-bottom: 40px; }\n.dbi-art-d20b5e .article-category { display: inline-block; background: rgba(255,255,255,0.2); padding: 8px 20px; border-radius: 25px; font-size: 0.9rem; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-header h1 { font-family: 'Montserrat', sans-serif; font-size: 2.3rem; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-header .subtitle { font-size: 1.1rem; opacity: 0.95; max-width: 700px; margin: 0 auto; }\n.dbi-art-d20b5e .intro-paragraph { font-size: 1.1rem; color: #555; padding: 30px; background: white; border-radius: 15px; border-left: 5px solid #5e5ed7; margin-bottom: 40px; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e h2 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; font-size: 1.9rem; margin: 50px 0 25px; padding-bottom: 15px; border-bottom: 3px solid #a9e2e4; }\n.dbi-art-d20b5e h3 { font-family: 'Montserrat', sans-serif; color: #5268c9; font-size: 1.35rem; margin: 35px 0 15px; }\n.dbi-art-d20b5e p { margin-bottom: 20px; text-align: justify; }\n.dbi-art-d20b5e .highlight-box { background: linear-gradient(135deg, #a9e2e4 0%, #d0f0f2 100%); padding: 30px; border-radius: 15px; margin: 30px 0; }\n.dbi-art-d20b5e .highlight-box h4 { font-family: 'Montserrat', sans-serif; color: #5268c9; margin-bottom: 15px; font-size: 1.2rem; }\n.dbi-art-d20b5e .tip-box { background: linear-gradient(135deg, #ffeca7 0%, #ffe88a 100%); padding: 25px; border-radius: 15px; margin: 25px 0; }\n.dbi-art-d20b5e .tip-box h4 { font-family: 'Montserrat', sans-serif; color: #5268c9; margin-bottom: 10px; }\n.dbi-art-d20b5e .warning-box { background: linear-gradient(135deg, #fde8ee 0%, #fcc8d6 100%); padding: 25px; border-radius: 15px; margin: 25px 0; border-left: 5px solid #e73469; }\n.dbi-art-d20b5e .warning-box h4 { font-family: 'Montserrat', sans-serif; color: #e73469; margin-bottom: 10px; }\n.dbi-art-d20b5e .stats-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin: 30px 0; }\n.dbi-art-d20b5e .stat-card { background: white; padding: 25px; border-radius: 15px; text-align: center; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e .stat-number { font-family: 'Montserrat', sans-serif; font-size: 2.5rem; font-weight: 800; color: #5e5ed7; display: block; }\n.dbi-art-d20b5e .stat-label { color: #666; font-size: 0.9rem; margin-top: 8px; }\n.dbi-art-d20b5e .comparison-table { width: 100%; border-collapse: collapse; margin: 30px 0; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e .comparison-table th { background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 15px 20px; text-align: left; font-family: 'Montserrat', sans-serif; }\n.dbi-art-d20b5e .comparison-table td { padding: 14px 20px; border-bottom: 1px solid #f0f0ff; background: white; vertical-align: top; }\n.dbi-art-d20b5e .comparison-table tr:last-child td { border-bottom: none; }\n.dbi-art-d20b5e .comparison-table tr:nth-child(even) td { background: #f8f8ff; }\n.dbi-art-d20b5e .program-card { background: white; border-radius: 20px; box-shadow: 0 8px 30px rgba(94,94,215,0.15); margin: 40px 0; padding: 30px; }\n.dbi-art-d20b5e .program-card h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; font-size: 1.4rem; margin-bottom: 15px; }\n.dbi-art-d20b5e .cta-button { display: inline-block; background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 14px 32px; border-radius: 30px; text-decoration: none; font-weight: 600; margin-top: 15px; }\n.dbi-art-d20b5e .method-card { background: white; border-radius: 15px; padding: 28px; margin: 22px 0; box-shadow: 0 5px 20px rgba(94,94,215,0.08); }\n.dbi-art-d20b5e .method-card.blue { border-left: 4px solid #5e5ed7; }\n.dbi-art-d20b5e .method-card.teal { border-left: 4px solid #a9e2e4; }\n.dbi-art-d20b5e .method-card.rose { border-left: 4px solid #e73469; }\n.dbi-art-d20b5e .method-card.yellow { border-left: 4px solid #ffeca7; border-top: 3px solid #ffeca7; }\n.dbi-art-d20b5e .method-card h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 12px; font-size: 1.1rem; }\n.dbi-art-d20b5e .method-card.teal h4 { color: #5268c9; }\n.dbi-art-d20b5e .method-card.rose h4 { color: #e73469; }\n.dbi-art-d20b5e .method-badge { display: inline-block; padding: 4px 12px; border-radius: 20px; font-size: 0.8rem; font-weight: 600; margin-bottom: 12px; }\n.dbi-art-d20b5e .badge-blue { background: #f0f0ff; color: #5e5ed7; }\n.dbi-art-d20b5e .badge-green { background: #e0f7f8; color: #5268c9; }\n.dbi-art-d20b5e .badge-rose { background: #fde8ee; color: #e73469; }\n.dbi-art-d20b5e .badge-yellow { background: #fff8dc; color: #8a6d00; }\n.dbi-art-d20b5e .checklist { background: white; padding: 30px; border-radius: 15px; box-shadow: 0 5px 20px rgba(94,94,215,0.1); margin: 25px 0; }\n.dbi-art-d20b5e .checklist h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 20px; }\n.dbi-art-d20b5e .checklist ul { list-style: none; padding: 0; }\n.dbi-art-d20b5e .checklist li { padding: 10px 0; border-bottom: 1px solid #f0f0ff; padding-left: 35px; position: relative; }\n.dbi-art-d20b5e .checklist li::before { content: '\u2714'; position: absolute; left: 0; color: #5e5ed7; font-weight: bold; }\n.dbi-art-d20b5e .checklist li:last-child { border-bottom: none; }\n.dbi-art-d20b5e .conclusion { background: linear-gradient(135deg, #f5f7fa 0%, #e8e8ff 100%); padding: 40px; border-radius: 20px; margin-top: 50px; }\n.dbi-art-d20b5e .conclusion h2 { border-bottom: none; margin-top: 0; }\n.dbi-art-d20b5e .article-footer { text-align: center; padding: 50px 20px; background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; border-radius: 30px 30px 0 0; margin-top: 60px; }\n.dbi-art-d20b5e .article-footer h3 { font-family: 'Montserrat', sans-serif; color: white; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-footer a { color: #ffeca7; text-decoration: none; font-weight: 600; }\n.dbi-art-d20b5e .footer-links { display: flex; gap: 20px; justify-content: center; flex-wrap: wrap; margin-top: 15px; }\n.dbi-art-d20b5e .faq-item { background: white; border-radius: 15px; padding: 25px 30px; margin: 15px 0; box-shadow: 0 3px 15px rgba(94,94,215,0.08); border-left: 4px solid #a9e2e4; }\n.dbi-art-d20b5e .faq-item h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 12px; font-size: 1.05rem; }\n.dbi-art-d20b5e .faq-item p { margin: 0; color: #555; }\n.dbi-art-d20b5e a { color: #5e5ed7; }\n@media (max-width: 768px) {\n.dbi-art-d20b5e .article-header h1 { font-size: 1.8rem; }\n.dbi-art-d20b5e .stats-grid { grid-template-columns: 1fr; }\n.dbi-art-d20b5e .article-header { padding: 40px 15px; }\n.dbi-art-d20b5e .container { padding: 15px; }\n.dbi-art-d20b5e h2 { font-size: 1.5rem; }\n.dbi-art-d20b5e .comparison-table { font-size: 0.9rem; }\n}<\/p>\n<\/style>\n<div class=\"dbi-art-d20b5e\">\n<article>\n<header class=\"article-header\">\n<div class=\"article-category\">\ud83e\udde0 Neurodegenerative diseases \u2014 SEP\/SLA\/Parkinson series<\/div>\n<h1>Multiple sclerosis (MS): symptoms and management<\/h1>\n<pee class=\"subtitle\">MS affects 120,000 people in France, mainly young women. A complex autoimmune disease, its symptoms vary from person to person and evolve unpredictably. This guide provides an overview.<\/pee>\n<\/header>\n<div class=\"container\">\n<div class=\"intro-paragraph\">\nMultiple sclerosis is one of the most common chronic neurological diseases in young adults. It is the leading cause of non-traumatic neurological disability before the age of 50 in France, characterized by an unpredictability that makes its management particularly complex. Understanding its mechanisms, clinical forms, and symptoms \u2014 particularly the often-overlooked cognitive disorders \u2014 is the first step to effectively support those affected.\n<\/div>\n<div class=\"stats-grid\">\n<div class=\"stat-card\"><span class=\"stat-number\">120,000<\/span><\/p>\n<div class=\"stat-label\">people affected by MS in France \u2014 3 new diagnoses per day<\/div>\n<\/div>\n<div class=\"stat-card\"><span class=\"stat-number\">85%<\/span><\/p>\n<div class=\"stat-label\">of cases are of the relapsing-remitting type \u2014 with relapses and remissions<\/div>\n<\/div>\n<div class=\"stat-card\"><span class=\"stat-number\">40\u201370%<\/span><\/p>\n<div class=\"stat-label\">experience cognitive disorders at some point in the disease<\/div>\n<\/div>\n<\/div>\n<h2>1. Mechanism and definition<\/h2>\n<pee>MS is an autoimmune disease in which the immune system mistakenly attacks the <strong>myelin<\/strong>, the insulating sheath that surrounds the nerve fibers of the central nervous system (brain and spinal cord). This attack forms areas of demyelination that disrupt or block the transmission of nerve signals. Over time, some nerve fibers are also irreparably damaged \u2014 this is neurodegeneration that leads to progressive disability.<\/pee>\n<pee>MS preferentially affects women (sex ratio 3:1), with a peak diagnosis between the ages of 20 and 40. Its etiology is multifactorial: genetic predisposition (25% concordance in monozygotic twins), environmental factors (vitamin D deficiency, smoking, Epstein-Barr virus infection), and immunological factors.<\/pee>\n<h2>2. Clinical forms<\/h2>\n<table class=\"comparison-table\">\n<thead>\n<tr>\n<th>Form<\/th>\n<th>Frequency<\/th>\n<th>Evolution<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Relapsing-remitting (RR)<\/strong><\/td>\n<td>85%<\/td>\n<td>Relapses separated by periods of stability (partial or complete remissions)<\/td>\n<\/tr>\n<tr>\n<td><strong>Primary progressive (PP)<\/strong><\/td>\n<td>15%<\/td>\n<td>Progressive deterioration from the start, without distinct relapses<\/td>\n<\/tr>\n<tr>\n<td><strong>Secondary progressive (SP)<\/strong><\/td>\n<td>Variable<\/td>\n<td>Evolution from an RR form to continuous progression<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>3. Symptoms<\/h2>\n<div class=\"method-card blue\">\n<div class=\"method-badge badge-blue\">\ud83d\ude34 Neurological fatigue<\/div>\n<h4>MS fatigue: much more than ordinary fatigue<\/h4>\n<pee>Present in 80% of patients, fatigue in MS is a deep neurological fatigue that is often disproportionate to effort. It is not relieved by rest, worsens with heat (Uhthoff phenomenon \u2014 heat further slows down demyelinated nerve conduction), and can occur even on remission days. It is often the most disabling symptom in daily and professional life.<\/pee>\n<\/div>\n<div class=\"method-card teal\">\n<div class=\"method-badge badge-green\">\ud83d\udc41\ufe0f Sensory and motor<\/div>\n<h4>Classic symptoms<\/h4>\n<pee>Sensory disorders (tingling, numbness, neuropathic pain) are often the first signs. <strong>Visual disorders<\/strong> \u2014 optic neuritis with blurred vision and eye pain \u2014 affect 20-25% of patients in their first relapse. <strong>Spasticity<\/strong> (rigid and contracted muscles), <strong>balance disorders<\/strong>, and <strong>muscle fatigue<\/strong> characterize the progression.<\/pee>\n<\/div>\n<div class=\"method-card rose\">\n<div class=\"method-badge badge-rose\">\ud83e\udde0 Cognitive<\/div>\n<h4>Cognitive disorders: the invisible disability of MS<\/h4>\n<pee>40 to 70% of people with MS experience cognitive disorders: <strong>slowed information processing<\/strong> (tasks taking longer), <strong>working memory disorders<\/strong> (difficulty retaining and manipulating information), <strong>divided attention disorders<\/strong> (difficulty managing multiple tasks simultaneously), and <strong>executive function disorders<\/strong>. These disorders are often invisible but have a profound impact on employment and relationships.<\/pee>\n<\/div>\n<h2>4. Treatments<\/h2>\n<pee>The management of MS relies on three axes. <strong>Disease-modifying treatments<\/strong> (interferons, glatiramer acetate, natalizumab, ocrelizumab) reduce the frequency and severity of relapses and slow progression \u2014 but do not cure the disease. <strong>Relapse treatment<\/strong> (corticosteroids by infusion) accelerates recovery during acute episodes. <strong>Rehabilitation and symptomatic support<\/strong> (physiotherapy, occupational therapy, speech therapy, neuropsychology) maintain quality of life and autonomy.<\/pee>\n<div class=\"program-card\">\n<h4>\ud83e\udde0 DYNSEO training and tools for MS<\/h4>\n<pee>\u2022 <a href=\"https:\/\/www.dynseo.com\/en\/courses\/sep-and-daily-life-maintaining-autonomy-and-preventing-complications-en\/\" target=\"_blank\"><strong>Training &#8220;MS and daily life&#8221;<\/strong><\/a> \u2014 maintain autonomy<!\u2013- [et_pb_br_holder] -\u2013><br \/>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/en\/courses\/multiple-sclerosis-in-an-institution-understanding-the-disease-and-adapting-professional-practice-en\/\" target=\"_blank\"><strong>Training &#8220;MS in institutions&#8221;<\/strong><\/a> \u2014 adapt your practice<!\u2013- [et_pb_br_holder] -\u2013><br \/>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/en\/courses\/fatigue-and-cognitive-disorders-in-ms-what-families-can-do-en\/\" target=\"_blank\"><strong>Training &#8220;Fatigue and cognitive disorders in MS&#8221;<\/strong><\/a><!\u2013- [et_pb_br_holder] -\u2013><br \/>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/en\/memory-test\/\" target=\"_blank\"><strong>DYNSEO Memory Test<\/strong><\/a> \u2014 assess cognitive impact<!\u2013- [et_pb_br_holder] -\u2013><br \/>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/\" target=\"_blank\"><strong>62 cognitive stimulation tools<\/strong><\/a><\/pee>\n<a href=\"https:\/\/www.dynseo.com\/en\/courses\/sep-and-daily-life-maintaining-autonomy-and-preventing-complications-en\/\" target=\"_blank\" class=\"cta-button\">Discover MS training \u2192<\/a>\n<\/div>\n<h2>FAQ<\/h2>\n<div class=\"faq-item\">\n<h4>What is MS?<\/h4>\n<pee>An autoimmune disease of the central nervous system in which the immune system attacks the myelin. It affects 120,000 people in France, mainly young women.<\/pee><\/div>\n<div class=\"faq-item\">\n<h4>What are the forms of MS?<\/h4>\n<pee>Relapsing-remitting (85%, relapses and remissions), primary progressive (15%, continuous deterioration), and secondary progressive (evolution from the RR form).<\/pee><\/div>\n<div class=\"faq-item\">\n<h4>Is MS fatigue different?<\/h4>\n<pee>Yes \u2014 it is a deep neurological fatigue, disproportionate, not relieved by rest, worsened by heat. It affects 80% of patients and is often the most disabling symptom.<\/pee><\/div>\n<div class=\"faq-item\">\n<h4>Does MS affect cognition?<\/h4>\n<pee>Yes \u2014 40-70% of patients experience cognitive disorders: slowing, working memory, divided attention. These disorders are often invisible but profoundly impact employment and social life.<\/pee><\/div>\n<div class=\"faq-item\">\n<h4>Is MS curable?<\/h4>\n<pee>Not yet. Disease-modifying treatments reduce the frequency of relapses and slow progression. Research is advancing on remyelination.<\/pee><\/div>\n<div class=\"conclusion\">\n<h2>Conclusion: living with MS<\/h2>\n<pee>MS is a complex, unpredictable, and multidimensional disease. Its cognitive symptoms, often overlooked in favor of visible motor symptoms, deserve special attention and specialized support. DYNSEO offers training for patients, relatives, and professionals, as well as cognitive stimulation tools tailored to the specific needs of people with MS.<\/pee>\n<\/div>\n<\/div>\n<footer class=\"article-footer\">\n<h3>DYNSEO Resources \u2014 MS<\/h3>\n<div class=\"footer-links\">\n<a href=\"https:\/\/www.dynseo.com\/en\/courses\/sep-and-daily-life-maintaining-autonomy-and-preventing-complications-en\/\" target=\"_blank\">MS daily life<\/a><br \/>\n<a href=\"https:\/\/www.dynseo.com\/en\/courses\/fatigue-and-cognitive-disorders-in-ms-what-families-can-do-en\/\" target=\"_blank\">MS fatigue<\/a><br \/>\n<a href=\"https:\/\/www.dynseo.com\/en\/memory-test\/\" target=\"_blank\">Memory Test<\/a><br \/>\n<a href=\"https:\/\/www.dynseo.com\/en\/our-tools\/\" target=\"_blank\">62 tools<\/a>\n<\/div>\n<\/footer>\n<\/article>\n<\/div>\n<p>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n<p>[et_pb_code]<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Qu'est-ce que la scl\u00e9rose en plaques et comment se d\u00e9veloppe-t-elle ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La scl\u00e9rose en plaques (SEP) est une maladie auto-immune dans laquelle le syst\u00e8me immunitaire attaque par erreur la my\u00e9line, la gaine isolante qui entoure les fibres nerveuses du syst\u00e8me nerveux central (cerveau et moelle \u00e9pini\u00e8re). Cette attaque forme des plaques de d\u00e9my\u00e9linisation qui perturbent ou bloquent la transmission des messages nerveux, entra\u00eenant avec le temps une neurod\u00e9g\u00e9n\u00e9rescence.\"}},{\"@type\":\"Question\",\"name\":\"Combien de personnes sont touch\u00e9es par la SEP en France ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP touche 120 000 personnes en France, principalement des femmes jeunes. On compte environ 3 nouveaux diagnostics par jour. C'est la premi\u00e8re cause de handicap non traumatique d'origine neurologique avant 50 ans en France.\"}},{\"@type\":\"Question\",\"name\":\"Quelle est la forme la plus courante de scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"85% des cas de SEP sont de forme r\u00e9currente-r\u00e9mittente, caract\u00e9ris\u00e9e par des pouss\u00e9es suivies de p\u00e9riodes de r\u00e9mission. Cette forme se distingue par son \u00e9volution impr\u00e9visible avec des phases d'aggravation et d'am\u00e9lioration des sympt\u00f4mes.\"}},{\"@type\":\"Question\",\"name\":\"Les troubles cognitifs sont-ils fr\u00e9quents dans la scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oui, 40 \u00e0 70% des personnes atteintes de SEP pr\u00e9sentent des troubles cognitifs \u00e0 un moment de la maladie. Ces troubles cognitifs sont souvent m\u00e9connus mais constituent un aspect important de la maladie qui n\u00e9cessite une prise en charge adapt\u00e9e.\"}},{\"@type\":\"Question\",\"name\":\"Pourquoi dit-on que la SEP est une maladie complexe \u00e0 accompagner ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP est complexe \u00e0 accompagner en raison de son impr\u00e9visibilit\u00e9. Ses sympt\u00f4mes varient d'une personne \u00e0 l'autre et \u00e9voluent de fa\u00e7on impr\u00e9visible, ce qui rend l'accompagnement particuli\u00e8rement difficile et n\u00e9cessite une approche personnalis\u00e9e.\"}},{\"@type\":\"Question\",\"name\":\"Quelle population est principalement touch\u00e9e par la scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP touche principalement des femmes jeunes et constitue l'une des maladies neurologiques chroniques les plus fr\u00e9quentes chez les adultes jeunes. Elle repr\u00e9sente la premi\u00e8re cause de handicap non traumatique d'origine neurologique avant l'\u00e2ge de 50 ans.\"}}]}<\/script>[\/et_pb_code]<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":150367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" admin_label=\"Article HTML\" _builder_version=\"4.16\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_row admin_label=\"Contenu\" _builder_version=\"4.16\" width=\"100%\" max_width=\"100%\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.16\" global_colors_info=\"{}\"][et_pb_code admin_label=\"HTML import\u00e9\" _builder_version=\"4.16\" global_colors_info=\"{}\"]<style type=\"text\/css\">\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Montserrat:wght@600;700;800&family=Poppins:wght@400;500;600&display=swap');\n        * { margin: 0; padding: 0; box-sizing: border-box; }\n.dbi-art-d20b5e { font-family: 'Poppins', sans-serif; line-height: 1.8; color: #333; background-color: #f8f9fa; }\n.dbi-art-d20b5e .container { max-width: 900px; margin: 0 auto; padding: 20px; }\n.dbi-art-d20b5e .article-header { background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 60px 20px; text-align: center; border-radius: 0 0 30px 30px; margin-bottom: 40px; }\n.dbi-art-d20b5e .article-category { display: inline-block; background: rgba(255,255,255,0.2); padding: 8px 20px; border-radius: 25px; font-size: 0.9rem; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-header h1 { font-family: 'Montserrat', sans-serif; font-size: 2.3rem; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-header .subtitle { font-size: 1.1rem; opacity: 0.95; max-width: 700px; margin: 0 auto; }\n.dbi-art-d20b5e .intro-paragraph { font-size: 1.1rem; color: #555; padding: 30px; background: white; border-radius: 15px; border-left: 5px solid #5e5ed7; margin-bottom: 40px; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e h2 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; font-size: 1.9rem; margin: 50px 0 25px; padding-bottom: 15px; border-bottom: 3px solid #a9e2e4; }\n.dbi-art-d20b5e h3 { font-family: 'Montserrat', sans-serif; color: #5268c9; font-size: 1.35rem; margin: 35px 0 15px; }\n.dbi-art-d20b5e p { margin-bottom: 20px; text-align: justify; }\n.dbi-art-d20b5e .highlight-box { background: linear-gradient(135deg, #a9e2e4 0%, #d0f0f2 100%); padding: 30px; border-radius: 15px; margin: 30px 0; }\n.dbi-art-d20b5e .highlight-box h4 { font-family: 'Montserrat', sans-serif; color: #5268c9; margin-bottom: 15px; font-size: 1.2rem; }\n.dbi-art-d20b5e .tip-box { background: linear-gradient(135deg, #ffeca7 0%, #ffe88a 100%); padding: 25px; border-radius: 15px; margin: 25px 0; }\n.dbi-art-d20b5e .tip-box h4 { font-family: 'Montserrat', sans-serif; color: #5268c9; margin-bottom: 10px; }\n.dbi-art-d20b5e .warning-box { background: linear-gradient(135deg, #fde8ee 0%, #fcc8d6 100%); padding: 25px; border-radius: 15px; margin: 25px 0; border-left: 5px solid #e73469; }\n.dbi-art-d20b5e .warning-box h4 { font-family: 'Montserrat', sans-serif; color: #e73469; margin-bottom: 10px; }\n.dbi-art-d20b5e .stats-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin: 30px 0; }\n.dbi-art-d20b5e .stat-card { background: white; padding: 25px; border-radius: 15px; text-align: center; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e .stat-number { font-family: 'Montserrat', sans-serif; font-size: 2.5rem; font-weight: 800; color: #5e5ed7; display: block; }\n.dbi-art-d20b5e .stat-label { color: #666; font-size: 0.9rem; margin-top: 8px; }\n.dbi-art-d20b5e .comparison-table { width: 100%; border-collapse: collapse; margin: 30px 0; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 20px rgba(94,94,215,0.1); }\n.dbi-art-d20b5e .comparison-table th { background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 15px 20px; text-align: left; font-family: 'Montserrat', sans-serif; }\n.dbi-art-d20b5e .comparison-table td { padding: 14px 20px; border-bottom: 1px solid #f0f0ff; background: white; vertical-align: top; }\n.dbi-art-d20b5e .comparison-table tr:last-child td { border-bottom: none; }\n.dbi-art-d20b5e .comparison-table tr:nth-child(even) td { background: #f8f8ff; }\n.dbi-art-d20b5e .program-card { background: white; border-radius: 20px; box-shadow: 0 8px 30px rgba(94,94,215,0.15); margin: 40px 0; padding: 30px; }\n.dbi-art-d20b5e .program-card h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; font-size: 1.4rem; margin-bottom: 15px; }\n.dbi-art-d20b5e .cta-button { display: inline-block; background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; padding: 14px 32px; border-radius: 30px; text-decoration: none; font-weight: 600; margin-top: 15px; }\n.dbi-art-d20b5e .method-card { background: white; border-radius: 15px; padding: 28px; margin: 22px 0; box-shadow: 0 5px 20px rgba(94,94,215,0.08); }\n.dbi-art-d20b5e .method-card.blue { border-left: 4px solid #5e5ed7; }\n.dbi-art-d20b5e .method-card.teal { border-left: 4px solid #a9e2e4; }\n.dbi-art-d20b5e .method-card.rose { border-left: 4px solid #e73469; }\n.dbi-art-d20b5e .method-card.yellow { border-left: 4px solid #ffeca7; border-top: 3px solid #ffeca7; }\n.dbi-art-d20b5e .method-card h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 12px; font-size: 1.1rem; }\n.dbi-art-d20b5e .method-card.teal h4 { color: #5268c9; }\n.dbi-art-d20b5e .method-card.rose h4 { color: #e73469; }\n.dbi-art-d20b5e .method-badge { display: inline-block; padding: 4px 12px; border-radius: 20px; font-size: 0.8rem; font-weight: 600; margin-bottom: 12px; }\n.dbi-art-d20b5e .badge-blue { background: #f0f0ff; color: #5e5ed7; }\n.dbi-art-d20b5e .badge-green { background: #e0f7f8; color: #5268c9; }\n.dbi-art-d20b5e .badge-rose { background: #fde8ee; color: #e73469; }\n.dbi-art-d20b5e .badge-yellow { background: #fff8dc; color: #8a6d00; }\n.dbi-art-d20b5e .checklist { background: white; padding: 30px; border-radius: 15px; box-shadow: 0 5px 20px rgba(94,94,215,0.1); margin: 25px 0; }\n.dbi-art-d20b5e .checklist h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 20px; }\n.dbi-art-d20b5e .checklist ul { list-style: none; padding: 0; }\n.dbi-art-d20b5e .checklist li { padding: 10px 0; border-bottom: 1px solid #f0f0ff; padding-left: 35px; position: relative; }\n.dbi-art-d20b5e .checklist li::before { content: '\u2714'; position: absolute; left: 0; color: #5e5ed7; font-weight: bold; }\n.dbi-art-d20b5e .checklist li:last-child { border-bottom: none; }\n.dbi-art-d20b5e .conclusion { background: linear-gradient(135deg, #f5f7fa 0%, #e8e8ff 100%); padding: 40px; border-radius: 20px; margin-top: 50px; }\n.dbi-art-d20b5e .conclusion h2 { border-bottom: none; margin-top: 0; }\n.dbi-art-d20b5e .article-footer { text-align: center; padding: 50px 20px; background: linear-gradient(135deg, #5e5ed7 0%, #5268c9 100%); color: white; border-radius: 30px 30px 0 0; margin-top: 60px; }\n.dbi-art-d20b5e .article-footer h3 { font-family: 'Montserrat', sans-serif; color: white; margin-bottom: 20px; }\n.dbi-art-d20b5e .article-footer a { color: #ffeca7; text-decoration: none; font-weight: 600; }\n.dbi-art-d20b5e .footer-links { display: flex; gap: 20px; justify-content: center; flex-wrap: wrap; margin-top: 15px; }\n.dbi-art-d20b5e .faq-item { background: white; border-radius: 15px; padding: 25px 30px; margin: 15px 0; box-shadow: 0 3px 15px rgba(94,94,215,0.08); border-left: 4px solid #a9e2e4; }\n.dbi-art-d20b5e .faq-item h4 { font-family: 'Montserrat', sans-serif; color: #5e5ed7; margin-bottom: 12px; font-size: 1.05rem; }\n.dbi-art-d20b5e .faq-item p { margin: 0; color: #555; }\n.dbi-art-d20b5e a { color: #5e5ed7; }\n@media (max-width: 768px) {\n.dbi-art-d20b5e .article-header h1 { font-size: 1.8rem; }\n.dbi-art-d20b5e .stats-grid { grid-template-columns: 1fr; }\n.dbi-art-d20b5e .article-header { padding: 40px 15px; }\n.dbi-art-d20b5e .container { padding: 15px; }\n.dbi-art-d20b5e h2 { font-size: 1.5rem; }\n.dbi-art-d20b5e .comparison-table { font-size: 0.9rem; }\n}\n\n<\/style>\n<div class=\"dbi-art-d20b5e\">\n<article>\n<header class=\"article-header\">\n<div class=\"article-category\">\ud83e\udde0 Neurodegenerative diseases \u2014 SEP\/SLA\/Parkinson series<\/div>\n<h1>Multiple sclerosis (MS): symptoms and management<\/h1>\n<p class=\"subtitle\">MS affects 120,000 people in France, mainly young women. A complex autoimmune disease, its symptoms vary from person to person and evolve unpredictably. This guide provides an overview.<\/p>\n<\/header>\n<div class=\"container\">\n<div class=\"intro-paragraph\">\nMultiple sclerosis is one of the most common chronic neurological diseases in young adults. It is the leading cause of non-traumatic neurological disability before the age of 50 in France, characterized by an unpredictability that makes its management particularly complex. Understanding its mechanisms, clinical forms, and symptoms \u2014 particularly the often-overlooked cognitive disorders \u2014 is the first step to effectively support those affected.\n<\/div>\n<div class=\"stats-grid\">\n<div class=\"stat-card\"><span class=\"stat-number\">120,000<\/span><div class=\"stat-label\">people affected by MS in France \u2014 3 new diagnoses per day<\/div><\/div>\n<div class=\"stat-card\"><span class=\"stat-number\">85%<\/span><div class=\"stat-label\">of cases are of the relapsing-remitting type \u2014 with relapses and remissions<\/div><\/div>\n<div class=\"stat-card\"><span class=\"stat-number\">40\u201370%<\/span><div class=\"stat-label\">experience cognitive disorders at some point in the disease<\/div><\/div>\n<\/div>\n\n<h2>1. Mechanism and definition<\/h2>\n<p>MS is an autoimmune disease in which the immune system mistakenly attacks the <strong>myelin<\/strong>, the insulating sheath that surrounds the nerve fibers of the central nervous system (brain and spinal cord). This attack forms areas of demyelination that disrupt or block the transmission of nerve signals. Over time, some nerve fibers are also irreparably damaged \u2014 this is neurodegeneration that leads to progressive disability.<\/p>\n<p>MS preferentially affects women (sex ratio 3:1), with a peak diagnosis between the ages of 20 and 40. Its etiology is multifactorial: genetic predisposition (25% concordance in monozygotic twins), environmental factors (vitamin D deficiency, smoking, Epstein-Barr virus infection), and immunological factors.<\/p>\n\n<h2>2. Clinical forms<\/h2>\n<table class=\"comparison-table\">\n<thead><tr><th>Form<\/th><th>Frequency<\/th><th>Evolution<\/th><\/tr><\/thead>\n<tbody>\n<tr><td><strong>Relapsing-remitting (RR)<\/strong><\/td><td>85%<\/td><td>Relapses separated by periods of stability (partial or complete remissions)<\/td><\/tr>\n<tr><td><strong>Primary progressive (PP)<\/strong><\/td><td>15%<\/td><td>Progressive deterioration from the start, without distinct relapses<\/td><\/tr>\n<tr><td><strong>Secondary progressive (SP)<\/strong><\/td><td>Variable<\/td><td>Evolution from an RR form to continuous progression<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<h2>3. Symptoms<\/h2>\n\n<div class=\"method-card blue\">\n<div class=\"method-badge badge-blue\">\ud83d\ude34 Neurological fatigue<\/div>\n<h4>MS fatigue: much more than ordinary fatigue<\/h4>\n<p>Present in 80% of patients, fatigue in MS is a deep neurological fatigue that is often disproportionate to effort. It is not relieved by rest, worsens with heat (Uhthoff phenomenon \u2014 heat further slows down demyelinated nerve conduction), and can occur even on remission days. It is often the most disabling symptom in daily and professional life.<\/p>\n<\/div>\n\n<div class=\"method-card teal\">\n<div class=\"method-badge badge-green\">\ud83d\udc41\ufe0f Sensory and motor<\/div>\n<h4>Classic symptoms<\/h4>\n<p>Sensory disorders (tingling, numbness, neuropathic pain) are often the first signs. <strong>Visual disorders<\/strong> \u2014 optic neuritis with blurred vision and eye pain \u2014 affect 20-25% of patients in their first relapse. <strong>Spasticity<\/strong> (rigid and contracted muscles), <strong>balance disorders<\/strong>, and <strong>muscle fatigue<\/strong> characterize the progression.<\/p>\n<\/div>\n\n<div class=\"method-card rose\">\n<div class=\"method-badge badge-rose\">\ud83e\udde0 Cognitive<\/div>\n<h4>Cognitive disorders: the invisible disability of MS<\/h4>\n<p>40 to 70% of people with MS experience cognitive disorders: <strong>slowed information processing<\/strong> (tasks taking longer), <strong>working memory disorders<\/strong> (difficulty retaining and manipulating information), <strong>divided attention disorders<\/strong> (difficulty managing multiple tasks simultaneously), and <strong>executive function disorders<\/strong>. These disorders are often invisible but have a profound impact on employment and relationships.<\/p>\n<\/div>\n\n<h2>4. Treatments<\/h2>\n<p>The management of MS relies on three axes. <strong>Disease-modifying treatments<\/strong> (interferons, glatiramer acetate, natalizumab, ocrelizumab) reduce the frequency and severity of relapses and slow progression \u2014 but do not cure the disease. <strong>Relapse treatment<\/strong> (corticosteroids by infusion) accelerates recovery during acute episodes. <strong>Rehabilitation and symptomatic support<\/strong> (physiotherapy, occupational therapy, speech therapy, neuropsychology) maintain quality of life and autonomy.<\/p>\n\n<div class=\"program-card\">\n<h4>\ud83e\udde0 DYNSEO training and tools for MS<\/h4>\n<p>\u2022 <a href=\"https:\/\/www.dynseo.com\/courses\/sep-et-vie-quotidienne-maintenir-lautonomie-et-prevenir-les-complications\/\" target=\"_blank\"><strong>Training \"MS and daily life\"<\/strong><\/a> \u2014 maintain autonomy<br>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/courses\/sclerose-en-plaques-en-etablissement-comprendre-la-maladie-et-adapter-sa-pratique-professionnelle\/\" target=\"_blank\"><strong>Training \"MS in institutions\"<\/strong><\/a> \u2014 adapt your practice<br>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/courses\/fatigue-et-troubles-cognitifs-dans-la-sep-ce-que-les-familles-peuvent-faire\/\" target=\"_blank\"><strong>Training \"Fatigue and cognitive disorders in MS\"<\/strong><\/a><br>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/test-memoire\/\" target=\"_blank\"><strong>DYNSEO Memory Test<\/strong><\/a> \u2014 assess cognitive impact<br>\n\u2022 <a href=\"https:\/\/www.dynseo.com\/nos-outils\/\" target=\"_blank\"><strong>62 cognitive stimulation tools<\/strong><\/a><\/p>\n<a href=\"https:\/\/www.dynseo.com\/courses\/sep-et-vie-quotidienne-maintenir-lautonomie-et-prevenir-les-complications\/\" target=\"_blank\" class=\"cta-button\">Discover MS training \u2192<\/a>\n<\/div>\n\n<h2>FAQ<\/h2>\n<div class=\"faq-item\"><h4>What is MS?<\/h4><p>An autoimmune disease of the central nervous system in which the immune system attacks the myelin. It affects 120,000 people in France, mainly young women.<\/p><\/div>\n<div class=\"faq-item\"><h4>What are the forms of MS?<\/h4><p>Relapsing-remitting (85%, relapses and remissions), primary progressive (15%, continuous deterioration), and secondary progressive (evolution from the RR form).<\/p><\/div>\n<div class=\"faq-item\"><h4>Is MS fatigue different?<\/h4><p>Yes \u2014 it is a deep neurological fatigue, disproportionate, not relieved by rest, worsened by heat. It affects 80% of patients and is often the most disabling symptom.<\/p><\/div>\n<div class=\"faq-item\"><h4>Does MS affect cognition?<\/h4><p>Yes \u2014 40-70% of patients experience cognitive disorders: slowing, working memory, divided attention. These disorders are often invisible but profoundly impact employment and social life.<\/p><\/div>\n<div class=\"faq-item\"><h4>Is MS curable?<\/h4><p>Not yet. Disease-modifying treatments reduce the frequency of relapses and slow progression. Research is advancing on remyelination.<\/p><\/div>\n\n<div class=\"conclusion\">\n<h2>Conclusion: living with MS<\/h2>\n<p>MS is a complex, unpredictable, and multidimensional disease. Its cognitive symptoms, often overlooked in favor of visible motor symptoms, deserve special attention and specialized support. DYNSEO offers training for patients, relatives, and professionals, as well as cognitive stimulation tools tailored to the specific needs of people with MS.<\/p>\n<\/div>\n\n<\/div>\n<footer class=\"article-footer\">\n<h3>DYNSEO Resources \u2014 MS<\/h3>\n<div class=\"footer-links\">\n<a href=\"https:\/\/www.dynseo.com\/courses\/sep-et-vie-quotidienne-maintenir-lautonomie-et-prevenir-les-complications\/\" target=\"_blank\">MS daily life<\/a>\n<a href=\"https:\/\/www.dynseo.com\/courses\/fatigue-et-troubles-cognitifs-dans-la-sep-ce-que-les-familles-peuvent-faire\/\" target=\"_blank\">MS fatigue<\/a>\n<a href=\"https:\/\/www.dynseo.com\/test-memoire\/\" target=\"_blank\">Memory Test<\/a>\n<a href=\"https:\/\/www.dynseo.com\/nos-outils\/\" target=\"_blank\">62 tools<\/a>\n<\/div>\n<\/footer>\n<\/article>\n<\/div>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n\n[et_pb_code]<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Qu'est-ce que la scl\u00e9rose en plaques et comment se d\u00e9veloppe-t-elle ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La scl\u00e9rose en plaques (SEP) est une maladie auto-immune dans laquelle le syst\u00e8me immunitaire attaque par erreur la my\u00e9line, la gaine isolante qui entoure les fibres nerveuses du syst\u00e8me nerveux central (cerveau et moelle \u00e9pini\u00e8re). Cette attaque forme des plaques de d\u00e9my\u00e9linisation qui perturbent ou bloquent la transmission des messages nerveux, entra\u00eenant avec le temps une neurod\u00e9g\u00e9n\u00e9rescence.\"}},{\"@type\":\"Question\",\"name\":\"Combien de personnes sont touch\u00e9es par la SEP en France ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP touche 120 000 personnes en France, principalement des femmes jeunes. On compte environ 3 nouveaux diagnostics par jour. C'est la premi\u00e8re cause de handicap non traumatique d'origine neurologique avant 50 ans en France.\"}},{\"@type\":\"Question\",\"name\":\"Quelle est la forme la plus courante de scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"85% des cas de SEP sont de forme r\u00e9currente-r\u00e9mittente, caract\u00e9ris\u00e9e par des pouss\u00e9es suivies de p\u00e9riodes de r\u00e9mission. Cette forme se distingue par son \u00e9volution impr\u00e9visible avec des phases d'aggravation et d'am\u00e9lioration des sympt\u00f4mes.\"}},{\"@type\":\"Question\",\"name\":\"Les troubles cognitifs sont-ils fr\u00e9quents dans la scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oui, 40 \u00e0 70% des personnes atteintes de SEP pr\u00e9sentent des troubles cognitifs \u00e0 un moment de la maladie. Ces troubles cognitifs sont souvent m\u00e9connus mais constituent un aspect important de la maladie qui n\u00e9cessite une prise en charge adapt\u00e9e.\"}},{\"@type\":\"Question\",\"name\":\"Pourquoi dit-on que la SEP est une maladie complexe \u00e0 accompagner ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP est complexe \u00e0 accompagner en raison de son impr\u00e9visibilit\u00e9. Ses sympt\u00f4mes varient d'une personne \u00e0 l'autre et \u00e9voluent de fa\u00e7on impr\u00e9visible, ce qui rend l'accompagnement particuli\u00e8rement difficile et n\u00e9cessite une approche personnalis\u00e9e.\"}},{\"@type\":\"Question\",\"name\":\"Quelle population est principalement touch\u00e9e par la scl\u00e9rose en plaques ?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"La SEP touche principalement des femmes jeunes et constitue l'une des maladies neurologiques chroniques les plus fr\u00e9quentes chez les adultes jeunes. Elle repr\u00e9sente la premi\u00e8re cause de handicap non traumatique d'origine neurologique avant l'\u00e2ge de 50 ans.\"}}]}<\/script>[\/et_pb_code]","_et_gb_content_width":"","footnotes":""},"categories":[2915],"tags":[],"class_list":["post-549626","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-conseils-des-coachs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/\" \/>\n<meta property=\"og:site_name\" content=\"DYNSEO - Educational apps &amp; brain training apps for all\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T02:59:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T02:59:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DYNSEO\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DYNSEO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/\"},\"author\":{\"name\":\"DYNSEO\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\"},\"headline\":\"Multiple Sclerosis (MS): Symptoms and Management\",\"datePublished\":\"2026-04-17T02:59:06+00:00\",\"dateModified\":\"2026-04-17T02:59:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/\"},\"wordCount\":813,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png\",\"articleSection\":[\"Les conseils des coachs\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/\",\"name\":\"Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png\",\"datePublished\":\"2026-04-17T02:59:06+00:00\",\"dateModified\":\"2026-04-17T02:59:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png\",\"width\":1080,\"height\":540,\"caption\":\"Keep your brain in shape with our fun applications\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/multiple-sclerosis-ms-symptoms-and-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Multiple Sclerosis (MS): Symptoms and Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"name\":\"Jeux de m\u00e9moire et stimulation cognitive\",\"description\":\"DYNSEO, and your brain is a new hero!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#organization\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"contentUrl\":\"https:\\\/\\\/www.dynseo.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-dynseo-new.png\",\"width\":5073,\"height\":1397,\"caption\":\"DYNSEO\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/#\\\/schema\\\/person\\\/78ef63df2ee64e0989bc68f8401b38d6\",\"name\":\"DYNSEO\",\"url\":\"https:\\\/\\\/www.dynseo.com\\\/en\\\/author\\\/justine\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/","og_locale":"en_US","og_type":"article","og_title":"Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all","og_url":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/","og_site_name":"DYNSEO - Educational apps &amp; brain training apps for all","article_published_time":"2026-04-17T02:59:06+00:00","article_modified_time":"2026-04-17T02:59:59+00:00","og_image":[{"width":1080,"height":540,"url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png","type":"image\/png"}],"author":"DYNSEO","twitter_misc":{"Written by":"DYNSEO","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#article","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/"},"author":{"name":"DYNSEO","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6"},"headline":"Multiple Sclerosis (MS): Symptoms and Management","datePublished":"2026-04-17T02:59:06+00:00","dateModified":"2026-04-17T02:59:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/"},"wordCount":813,"publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png","articleSection":["Les conseils des coachs"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/","url":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/","name":"Multiple Sclerosis (MS): Symptoms and Management - DYNSEO - Educational apps &amp; brain training apps for all","isPartOf":{"@id":"https:\/\/www.dynseo.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#primaryimage"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#primaryimage"},"thumbnailUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png","datePublished":"2026-04-17T02:59:06+00:00","dateModified":"2026-04-17T02:59:59+00:00","breadcrumb":{"@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#primaryimage","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2025\/04\/DYNSEO-demande-de-PCH-avec-nos-programme-de-jeux-de-memoire4.png","width":1080,"height":540,"caption":"Keep your brain in shape with our fun applications"},{"@type":"BreadcrumbList","@id":"https:\/\/www.dynseo.com\/en\/multiple-sclerosis-ms-symptoms-and-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dynseo.com\/en\/"},{"@type":"ListItem","position":2,"name":"Multiple Sclerosis (MS): Symptoms and Management"}]},{"@type":"WebSite","@id":"https:\/\/www.dynseo.com\/en\/#website","url":"https:\/\/www.dynseo.com\/en\/","name":"Jeux de m\u00e9moire et stimulation cognitive","description":"DYNSEO, and your brain is a new hero!","publisher":{"@id":"https:\/\/www.dynseo.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dynseo.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.dynseo.com\/en\/#organization","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","contentUrl":"https:\/\/www.dynseo.com\/wp-content\/uploads\/2022\/05\/logo-dynseo-new.png","width":5073,"height":1397,"caption":"DYNSEO"},"image":{"@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.dynseo.com\/en\/#\/schema\/person\/78ef63df2ee64e0989bc68f8401b38d6","name":"DYNSEO","url":"https:\/\/www.dynseo.com\/en\/author\/justine\/"}]}},"_links":{"self":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/549626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/comments?post=549626"}],"version-history":[{"count":2,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/549626\/revisions"}],"predecessor-version":[{"id":549628,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/posts\/549626\/revisions\/549628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media\/150367"}],"wp:attachment":[{"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/media?parent=549626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/categories?post=549626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dynseo.com\/en\/wp-json\/wp\/v2\/tags?post=549626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}